Corning + China National Biotec Group
Corning
Corning, New York · 1 relationship
Active relationship
Joint Venture · 2020–present
China National Biotec Group
Beijing, Beijing · 1 relationship
Analysis
Corning Pharmaceutical Glass Co., Ltd. was established in Bengbu, Anhui, through a 2020 joint-venture agreement between Corning and Bengbu Innovation Venture Capital Co., Ltd. [1] Corning described the project as a local partnership intended to add pharmaceutical-glass capacity during increased demand associated with COVID-19 vaccine and injectable-drug production. [1] The planned facility was designed for 20,000 metric tons per year of high-quality borosilicate tubing and was expected to create about 200 local jobs. [1]
By November 2021, Corning reported that the plant had begun operating in September and had reached its mass-production ceremony. [2] China National Biotec Group joined Corning and Bengbu Innovation Venture Capital as a co-investor, making the operating structure a three-party investment rather than the two-party arrangement described in the original announcement. [2] Corning said the added capacity would support Type I borosilicate tubing for China and that the site introduced Velocity vials for vaccine packaging and high-speed filling-line applications. [2]
Corning’s 2021 annual report lists the Bengbu tubing facility among its new life-sciences production assets. [3] The same report places the site within a broader pharmaceutical-packaging portfolio that included Valor glass vials, Velocity vials, and tubing, but it does not attribute the portfolio-wide vaccine-dose figure specifically to Bengbu. [3] The arrangement therefore combines Corning’s glass and pharmaceutical-packaging technology with CNBG’s biopharmaceutical position and local investment support. [2]
Corning’s 2024 China overview still lists Corning Pharmaceutical Glass Co., Ltd. in Bengbu as a joint venture and identifies mass production as beginning in November 2021. [4] A later Corning account says the Bengbu plant added a rooftop solar array with 3,210 panels across about 15,800 square meters, estimated annual generation of 1.73 million kWh, and potential annual carbon-dioxide reduction of 1,585 metric tons at full capacity. [5] Those environmental figures are Corning’s published site-level estimates rather than independently audited partnership-performance data. [5]
Participants
Continue through either entity
Corning, New York · 1 record in this database
Corning Incorporated is a materials-science and manufacturing company founded in 1851 and headquartered in Corning, New York. Corning says its core technical disciplines are glass science, ceramic science, and optical physics, supported by manufacturing platforms including vapor deposition, fusion, precision forming, and extrusion. Its 2025 corporate profile lists approximately 70,000 employees, 78 manufacturing sites, more than nine research-and-development facilities, and $16.41 billion in 2025 core sales. [1] [2]
The company’s history links scientific research to industrial products. Corning’s history account says the company was already using research and development as a differentiator in 1851, supplied Thomas Edison with glass bulbs for electric-light applications by 1880, and later developed products across changing technology markets. Corning also identifies its 1970 invention of low-loss optical fiber as the beginning of its role in the telecommunications revolution. [2] [3]
Corning currently organizes its market activity around life sciences, mobile consumer electronics, optical communications, display, and automotive applications. Its products include drug-discovery and bioproduction tools, damage-resistant cover glass, optical fiber and connectivity hardware, precision display glass, and automotive glass and ceramic emissions-control products. The company’s filings and market descriptions present these as engineered materials and components sold into larger industrial and consumer ecosystems rather than as finished consumer brands in every market. [1] [4]
Corning’s business model depends on repeatedly transferring materials expertise into new applications and scaling the associated manufacturing processes. The company describes its market-access platforms as Optical Communications, Mobile Consumer Electronics, Display, Automotive, and Life Sciences, with research and customer collaboration connecting the platforms. In consumer electronics, for example, Corning says glass science and optical design support cover glass, anti-reflective glass, and other components for mobile and connected devices. [5]
For this database, Corning should be read as the parent company rather than as a synonym for an individual joint venture or operating subsidiary. Its life-sciences, pharmaceutical-technology, glass, and ceramics capabilities can explain why Corning appears alongside partners in advanced-materials or glass-manufacturing records, while the specific venture remains a separate legal and operational entity. [1] [4]
Beijing, Beijing · 1 record in this database
China National Biotec Group (CNBG) is the core organization of Sinopharm’s biopharmaceutical sector. [1] Sinopharm says that sector contains more than 20 production enterprises with CNBG at its center, while CNBG’s current English site describes the organization as a leading Chinese biopharmaceutical company and reports that it produced about 3.6 billion vaccine doses between 2014 and 2024. [1] [2]
A member profile published by the Developing Countries Vaccine Manufacturers Network describes CNBG as an integrated organization covering research and development, production, sales and postgraduate training. [3] It lists 11 secondary subsidiaries, 69 sub-secondary companies and more than 10,000 employees, with six business segments: human vaccines, blood products, medical aesthetics, animal healthcare, biotherapeutics and medical diagnostics. [3] These organizational figures come from the network profile and are not presented here as a newly audited 2026 count. [3]
CNBG’s current product activity includes seasonal influenza vaccination. [4] Sinopharm reported that the quadrivalent split-virion inactivated influenza vaccine developed by its Changchun Institute of Biological Products received release approval on April 16, 2025 and entered the market for the 2025–26 season, using influenza strains recommended by the World Health Organization. [4]
CNBG also became internationally visible through the COVID-19 vaccine developed by its Beijing Institute of Biological Products. [5] On May 7, 2021, the World Health Organization listed the Sinopharm vaccine for emergency use and identified the producer as Beijing Bio-Institute of Biological Products, a CNBG subsidiary; WHO described it as an inactivated SARS-CoV-2 vaccine and documented its quality, safety, efficacy and suitability assessment. [5]
Taken together, these sources show CNBG as a vertically integrated vaccine-and-biologics network within a state-owned pharmaceutical group, combining research institutes, manufacturing companies, diagnostics and blood-product businesses with domestic and international public-health supply. [1] [3] [5] The profile distinguishes current organizational and product information from the dated regulatory milestone rather than implying that the 2021 emergency-use listing is a current authorization decision. [1] [3] [5]